Veeva Systems (VEEV) Gains 0.38% While S&P 500 and Nasdaq Move Higher Trading Volume Places at 422nd in Activity

Market Overview

On February 25, 2026, Veeva Systems (VEEV) ended the trading session up by 0.38%, trailing behind the S&P 500’s 0.77% and the Nasdaq’s 1.05% gains. The stock closed at $176.46, marking a slight recovery after a 23.2% drop over the past month. Trading volume reached $310 million, placing VEEV 422nd in daily market activity. Despite recent fluctuations, Veeva’s share price remains 20.28% below its 52-week peak of $310.50, and its forward price-to-earnings ratio stands at 20.28, which is under the industry average of 21.37.

Main Factors Influencing Veeva’s Stock

Upcoming Earnings and Share Repurchase Program

Veeva is scheduled to announce its fourth-quarter 2026 results on March 4, 2026. Analysts expect earnings per share of $1.92 and revenue of $810.95 million. The company’s board recently approved a $2 billion share buyback plan, authorizing the repurchase of up to 5.5% of outstanding shares—a move that signals management’s belief that the stock is undervalued. While buybacks can help support the share price, the effect may be limited due to recent selling by institutional investors.

Analyst Ratings and Price Target Changes

Although Veeva maintains a “Moderate Buy” consensus, analysts have become more cautious. UBS and JPMorgan lowered their price targets to $200 and $296, respectively, while Citigroup and Barclays reduced theirs to $319 and $305. These revisions reflect concerns about increased competition from Salesforce and the complexities involved in transitioning clients to Veeva’s Vault CRM platform. On a positive note, Truist Financial upgraded VEEV to a “Buy,” citing the company’s significant potential for AI-driven transformation in both clinical and commercial segments.

Institutional and Insider Transactions

Recent activity among major shareholders has been mixed. Citigroup boosted its holdings by 69.9% in the third quarter of 2026, and both Norges Bank and AQR Capital Management increased their investments by $384 million and $526 million, respectively. In contrast, Artisan Mid Cap Fund exited its position in the fourth quarter of 2025, and insider Thomas D. Schwenger reduced his stake by 4.13%. This divergence highlights a balance between confidence in Veeva’s long-term prospects and short-term profit-taking.

Strategic Direction and Competitive Landscape

Veeva’s CRM products now contribute 20% to total revenue, down from 25% two years ago, reflecting a shift toward a broader range of solutions such as Vault. CEO Peter Gassner has identified artificial intelligence as a key growth catalyst, with plans to implement AI across commercial, safety, and clinical areas by the end of the year. However, the company faces challenges, including delays in CRM migrations and aggressive competition from Salesforce, which could impact market share.

Valuation and Future Prospects

With a forward P/E of 20.28 and a PEG ratio of 0.85, Veeva appears attractively valued relative to its growth outlook. Nevertheless, a 20.28% decline over the past year signals investor concerns about the company’s ability to execute in the near term. Analysts forecast full-year 2026 earnings per share of $7.97 and revenue of $3.14 billion, but achieving these goals will depend on resolving CRM migration issues and accelerating AI integration. The cautious stance among analysts and some institutional investors suggests a wait-and-see approach, with upside potential hinging on positive earnings surprises and strategic execution.

Summary

Veeva’s current market position reflects a mix of strong fundamentals—such as its leadership in life sciences software—and ongoing challenges, including competitive threats and operational risks. The share repurchase initiative and AI strategy provide reasons for optimism over the long term, but recent analyst downgrades and institutional selling highlight prevailing market uncertainty. Investors are likely to focus on the upcoming March 4 earnings report, where results above $1.92 in EPS and $811 million in revenue could spark renewed interest. For now, VEEV is rated a “Moderate Buy” with an average price target of $300.50, but its future trajectory will depend on how well the company addresses execution risks and maintains its valuation.